ABBOTT LABORATORIES AND NAPRO BIOTHERAPEUTICS FILE PACLITAXEL ANDA
"Abbott is building a superior portfolio of oncology products," said Christopher B. Begley, senior vice president, hospital products, Abbott Laboratories. "Submitting the paclitaxel ANDA is a major milestone in Abbott's plan to expand our presence in the oncology market."
"We are very hopeful that soon oncologists and cancer patients in the United States will have another high quality paclitaxel option," commented Leonard P. Shaykin, chairman and chief executive officer, NaPro BioTherapeutics.
Other news from the department research and development
Get the chemical industry in your inbox
From now on, don't miss a thing: Our newsletter for the chemical industry, analytics, lab technology and process engineering brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.